Regulatorische Updates
15. Sept. 2026•1 Min. Lesezeit
FDA Approves Teva’s Methylphenidate Extended‑Release Capsules (ANDA 078873)
The FDA approved ANDA 078873 for Teva’s methylphenidate hydrochloride extended‑release capsules (40 mg, 50 mg, 60 mg). All listed products are currently discontinued.
Regulatorische Updates
13. Sept. 2026•1 Min. Lesezeit
FDA Approves Teva Methylphenidate Hydrochloride ER Capsules (ANDA 077707)
FDA has approved Teva Pharm’s methylphenidate hydrochloride extended‑release capsules in 10 mg, 20 mg and 30 mg strengths under ANDA 077707.
Regulatorische Updates
2. Sept. 2026•1 Min. Lesezeit
FDA Approves Methylphenidate Hydrochloride Oral Solution (ANDA 207417)
FDA has approved ANDA 207417 for methylphenidate hydrochloride oral solution, 5 mg/5 mL and 10 mg/5 mL strengths, manufactured by Ascent Pharmaceuticals.